BOT and Queensland Institute for Molecular Bioscience have confirmed that CBD has antimicrobial properties, particularly in the fighting of antibiotic resistance. BOT has now advanced its BTX1801 antibiotic formulation to the clinic and will be commencing a Phase 2a clinical study on S.aureus or Golden Staph. The aim of the study is to decolonise S.aureus in the noses of healthy volunteers. S.aureus is a source of post-surgical severe infections. We maintain our SPEC BUY recommendation and target price of $0.29.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.